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Objectives The aim of this study was to evaluate associations of 25-hydroxyvitamin D (25-OHD) and parathyroid hormone
(PTH) concentrations separately and in combination with incident cardiovascular events and mortality during
14 years of follow-up in the CHS (Cardiovascular Health Study).
Background Vitamin D deficiency and PTH excess are common in older adults and may adversely affect cardiovascular health.
Methods A total of 2,312 participants who were free of cardiovascular disease at baseline were studied. Vitamin D and intact
PTH were measured from previously frozen serum using mass spectrometry and a 2-site immunoassay. Outcomes
were adjudicated cases of myocardial infarction, heart failure, cardiovascular death, and all-cause mortality.
Results There were 384 participants (17%) with serum 25-OHD concentrations 15 ng/ml and 570 (25%) with serum PTH
concentrations 65 pg/ml. After adjustment, each 10 ng/ml lower 25-OHD concentration was associated with a 9%
greater (95% confidence interval [CI]: 2% to 17% greater) relative hazard of mortality and a 25% greater (95% CI: 8%
to 44% greater) relative hazard of myocardial infarction. Serum 25-OHD concentrations 15 ng/ml were associated
with a 29% greater (95% CI: 5% to 55% greater) risk for mortality. Serum PTH concentrations 65 pg/ml were asso-
ciated with a 30% greater risk for heart failure (95% CI: 6% to 61% greater) but not other outcomes. There was no
evidence of an interaction between serum 25-OHD and PTH concentrations and cardiovascular events.
Conclusions Among older adults, 25-OHD deficiency is associated with myocardial infarction and mortality; PTH excess is
associated with heart failure. Vitamin D and PTH might influence cardiovascular risk through divergent
pathways. (J Am Coll Cardiol 2011;58:1433–41) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.03.069Disturbances in mineral metabolism are common in older
adults and may adversely affect cardiovascular health (1,2).
Older age is associated with lower circulating concentrations
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2011, accepted March 10, 2011.of 25-hydroxyvitamin D (25-OHD), impaired vitamin D
activation within the kidney, and a rise in serum parathyroid
hormone (PTH) concentrations (3,4). Disturbances in vi-
tamin D and PTH metabolic axes may increase cardiovas-
cular risk through diverse pathways (1,5,6). In experimental
See page 1442
models, vitamin D deficiency activates the renin-angiotensin
system, stimulates inflammatory cytokines, and promotes
cardiomyocyte growth (7–9). PTH excess increases intra-
cellular calcium in target tissues and is associated with
hypertension, cardiac valve calcification, and left ventricular
hypertrophy (10,11).
Previous studies of mineral metabolism and cardiovascu-
lar risk have generally focused on middle-aged populations
and have evaluated 25-OHD and PTH concentrations
separately. In the present study, we evaluated 25-OHD and
PTH concentrations together in a general population of
2,312 ambulatory older adults who were free of clinical
cardiovascular disease at baseline. We assessed associations
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ers with adjudicated cases of in-
cident myocardial infarction, in-
cident heart failure, cardiovascular
death, and all-cause mortality
during 14 years of follow-up. We
hypothesized that lower 25-
OHD and higher PTH levels
would be associated with cardio-
vascular events and that associations would be strongest in
the presence of both disturbances, because PTH represents
an endogenous biologic marker of inadequate vitamin D
stores (12,13).
Methods
Study population. The CHS (Cardiovascular Health
tudy) is a prospective cohort study of clinical and subclin-
cal cardiovascular disease among older patients (14). In
989 and 1990, the CHS enrolled 5,201 ambulatory men
nd women age 65 years and older from Medicare eligibility
ists in Forsyth County, North Carolina; Sacramento
Abbreviations
and Acronyms
GFR  glomerular filtration
rate
PTH  parathyroid hormone
25-OHD  25-
hydroxyvitamin D
Figure 1 Flow Diagram of the Study Population
Exclusions are shown on the right side of the figure; additions to the study popula
CHS  Cardiovascular Health Study; TIA  transient ischemic attack; 25-OHD  2County, California; Washington County, Maryland; and
Pittsburgh, Pennsylvania. The CHS enrolled an additional
687 African American participants in 1992 and 1993.
Exclusion criteria included the use of a wheelchair in the
home, institutionalization, the need for a proxy respondent
to provide informed consent, plans to move from the area
within 3 years, and current treatment for cancer. Each
center’s institutional review board approved the study, and
all participants provided informed consent.
We evaluated CHS participants at the time of their 1992
and 1993 examinations. To focus on incident cardiovascular
events, we excluded participants who had prevalent cardio-
vascular disease at the time of the 1992 and 1993 CHS
exams, defined as any 1 of the following conditions: coro-
nary heart disease, heart failure, stroke, transient ischemic
attack, claudication, atrial fibrillation, pacemaker, or im-
plantable cardioverter-defibrillator (Fig. 1). CHS investiga-
tors determined prevalent cardiovascular conditions by re-
view of medical records, electrocardiographic findings,
participant responses to questionnaires, and interim events
that occurred between the baseline and 1992 and 1993 CHS
re shown on the left.
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who had inadequate serum volumes (500 l) to perform
the mineral metabolism measurements, 4 participants who
had implausible 25-OHD concentrations (100 ng/ml),
and 4 participants who were taking lithium, which may alter
calcium metabolism, resulting in a final study sample of
2,312 participants. Compared with participants excluded
because of inadequate sample volumes, included subjects
were older (73.9 years vs. 71.9 years) and more likely to be
Caucasian (85% vs. 75%).
Measurement of mineral metabolism variables. The
Laboratory for Clinical Biochemistry Research at the Uni-
versity of Vermont stored serum samples at 70°C using
established methods, which have demonstrated long-term
stability for serum markers of coagulation, fibrinolysis, and
inflammation (16). The University of Washington Clinical
Nutrition Research Unit performed mineral metabolism
measurements from serum collected during the 1992 and
1993 CHS exams. Total 25-OHD (25-OHD2  25-
OHD3) was measured using high-performance liquid chro-
matography and tandem mass spectrometry on a Waters
Quattro micro mass spectrometer (Waters, Milford, Mas-
sachusetts). The interassay coefficient of variation was
3.4%. Intact serum PTH was quantified using a 2-site
immunoassay on a Beckman UniCel DxI clinical analyzer
(Beckman Coulter, Brea, California). The reference range is
17 to 66 pg/ml, as determined from the central 95% of
values from 43 normal laboratory personnel with normal
25-OHD concentrations in March 2005. The interassay
coefficient of variation for PTH was 4.5% at 37 pg/ml.
Serum nonionized total calcium levels were measured using
indirect potentiometry, and serum phosphorus levels were
measured using a timed-rate colorimetric reaction method
with ammonium molybdate on a Beckman DxC Synchron
analyzer (Beckman Coulter).
Ascertainment of cardiovascular outcomes. Study out-
comes were all-cause mortality, cardiovascular mortality,
incident heart failure, and incident myocardial infarction.
CHS investigators identified potential cardiovascular events
semiannually via telephone surveillance and annually by
repeat interviews and examinations. The CHS events com-
mittee adjudicated cardiovascular events using available
hospital discharge summaries, diagnostic test reports, sur-
gical and radiologic findings, consultation reports, autopsies,
and death certificates (17). The committee defined heart
failure by a physician diagnosis of heart failure plus docu-
mentation of symptoms and signs of heart failure, pulmo-
nary edema on chest x-ray, or specific medical treatment for
heart failure. Echocardiographic results, when available,
were also considered during adjudication. The committee
defined acute myocardial infarction using an algorithm that
included elements of chest pain, cardiac enzymes, and
electrocardiographic changes. The committee defined car-
diovascular mortality as death due to acute myocardial
infarction, atherosclerotic coronary heart disease, ischemic
or hemorrhagic stroke, or other cardiovascular cause (rup-tured aortic aneurysm, peripheral vascular disease, valvular
heart disease, or pulmonary embolism). Cardiovascular
event data were complete through June 30, 2007. Because
participant data are linked with Medicare records and the
National Death Index, follow-up is considered to be 100%
complete for each of the study outcomes evaluated here.
Measurement of other study variables. Trained CHS
study personnel conducted standardized interviews, which
queried demographics, health status, smoking status, and
alcohol use (14). Study participants were asked about the
frequency and duration of 15 common leisure-time activities
during the previous 2 weeks, and CHS investigators calcu-
lated a total weighted leisure time physical activity score on
the basis of these responses. CHS study personnel assessed
prescription and over-the-counter medication use, including
vitamin D supplements, by instructing participants to bring
in all of their medications and directly transcribing the
medication bottle labels. We queried medication lists to
identify vitamin D and calcium supplement use. CHS study
personnel measured blood pressure in triplicate 5 min apart
with the participant seated and performed phlebotomy
under fasting conditions.
CHS investigators defined diabetes as a fasting glucose
level 7.0 mmol/l or the use of insulin or an oral hypogly-
cemic medication. We calculated body mass index as
height/(weight)2, where height and weight were measured
in meters and kilograms, respectively. We analyzed educa-
tion level as none through grade 9, high school, and
professional or vocational. The Laboratory for Clinical
Biochemistry Research analyzed blood specimens for albu-
min, total and high-density lipoprotein cholesterol, creati-
nine, and C-reactive protein. Low-density lipoprotein cho-
lesterol was calculated using the Friedewald equation. CHS
investigators measured cystatin C levels from previously
collected serum samples stored at 70°C using a particle-
enhanced immunonephelometric assay with a nephelometer
(BNII, Siemens Healthcare Diagnostics, Inc, Deerfield,
Illinois) (18). We calculated estimated glomerular filtration
rate (GFR) as estimated GFRcystatin C  76.7  (cystatin
)1.19. This equation, derived in a recent pooling study of
3,418 adults who underwent simultaneous cystatin C mea-
surements and gold-standard radionucleotide measurements
of GFR, explains approximately 82% of the variation in
directly measured GFR in the setting of chronic kidney
disease (19).
Statistical analysis. We analyzed 25-OHD as a continu-
ous variable because functional analyses revealed linear
associations of serum 25-OHD concentrations with study
outcomes. We also evaluated 25-OHD according to previ-
ously published categories (20–22). We analyzed serum
PTH concentrations as 65 pg/ml versus 65 pg/ml,
because functional analyses revealed threshold associations
of serum PTH concentration 65 pg/ml with each of the
study outcomes and because 65 pg/ml represents the upper
limit of normal for this assay on the basis of the central 95%
of values from healthy subjects who had normal 25-OHD
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a serum PTH concentration 65 pg/ml plus a serum
calcium concentration10.2 mg/dl, as previously published
(23). We used Spearman’s correlation to describe univar-
iate associations between serum 25-OHD and PTH
concentrations.
We defined time at risk as the elapsed time from the 1992
and 1993 examinations until the first occurrence of each
outcome of interest. We censored analyses of nonfatal
outcomes for mortality and censored analyses of cardiovas-
cular mortality for noncardiovascular death. We constructed
nested Cox proportional hazards models to estimate the
relative hazard of each study outcome after adjustment for
relevant confounding variables (24). A basic model included
25-OHD and PTH levels and adjusted for age, race, sex,
season of the year, and clinic site. A second model added
cardiovascular risk factors (diabetes, antihypertensive med-
ications, smoking, education, physical activity, body mass
index, systolic blood pressure, C-reactive protein, and total
and high-density lipoprotein cholesterol), and serum con-
centrations of calcium and phosphorus. A third model
added GFR, estimated by serum cystatin C concentrations,
to separately describe the confounding influence of kidney
function. We analyzed kilocalories of physical activity, body
mass index, systolic blood pressure, and levels of CRP,
lipids, calcium, phosphorus, and estimated GFR as contin-
uous variables in the multivariate models. We assessed the
functional associations of 25-OHD and PTH concentra-
tions with study outcomes by constructing spline models
after basic adjustment for covariates specified in model 1.
The proportional hazards assumption was satisfied for all
models (p  0.20), indicating statistically similar relative
risks of each study outcome over time.
We looked for evidence of an interaction between
25-OHD deficiency and PTH excess by calculating the
relative excess risk of interaction. A relative excess risk of
interaction of 0 indicates no additive biological interaction.
We performed stratified analyses to explore whether asso-
ciations of 25-OHD with study outcomes might differ
according to baseline characteristics. We conducted analyses
using S-Plus version 8.0 (Tibco, Seattle, Washington) and
SPSS version 15.0.1.1 (SPSS Inc., Chicago, Illinois).
Results
Description of vitamin D and PTH concentrations. Se-
um 25-OHD concentrations were normally distributed,
ith a mean value of 25.2 10.2 ng/ml (interquartile range:
17.8 to 31.5 ng/ml). The prevalences of vitamin D defi-
ciency (15 ng/ml) and insufficiency (15 to 30 ng/ml) were
16.6% and 53.9%, respectively. Serum 25-OHD concentra-
tions were highest among participants from the Sacramento
site (mean 26.4  10.5 ng/ml) and lowest among partici-
pants from the Pittsburgh site (mean 24.4  11.5 ng/ml).
he distribution of serum PTH concentrations was right
kewed, with a median value of 51 pg/ml (SD 29.7 pg/ml;nterquartile range: 39 to 65 pg/ml). Serum 25-OHD
oncentrations were inversely correlated with serum PTH
oncentrations (correlation coefficient  0.317).
Associations of vitamin D and PTH with baseline
characteristics. Lower serum 25-OHD concentrations
were related to African American race, female sex, measure-
ment during winter months, prevalent diabetes, current
smoking, greater body mass index, lesser physical activity,
higher systolic blood pressure, and higher serum CRP
concentrations (Table 1). The prevalence of vitamin D
deficiency was more than 3-fold greater among African
Americans compared with Caucasians (42.9% vs. 12.2%).
Serum 25-OHD concentrations were not associated with
estimated GFR. Higher serum PTH concentrations were
associated with African American race, female sex, higher
systolic blood pressure, and lower estimated GFR. Serum
calcium and phosphorus concentrations did not vary across
categories of 25-OHD, although serum phosphorus con-
centrations were slightly lower among participants who had
serum PTH concentrations 65 pg/ml.
Associations of 25-OHD with study outcomes. During a
median follow-up period of 14.0 years (interquartile range:
8.5 to 14.6 years), there were 1,226 deaths, of which 389
(32%) were classified as cardiovascular, 504 incident cases of
heart failure, and 299 incident myocardial infarctions. In a
minimally adjusted model that included serum PTH con-
centration, age, race, sex, season, and clinic site, each 10
ng/ml lower serum 25-OHD concentration was associated
with all-cause mortality and incident myocardial infarction
but not with cardiovascular death or incident heart failure
(Table 2). Further adjustment for traditional cardiovascular
risk factors plus serum calcium and phosphorus modestly
attenuated associations of 25-OHD with mortality and
myocardial infarction; adjustment for estimated kidney
function did not appreciably alter these associations. After
full adjustment, each 10 ng/ml lower 25-OHD concentra-
tion was associated with a 9% greater relative risk for
all-cause mortality (95% confidence interval: 2% to 17%
greater; p  0.012) and a 25% greater relative risk for
ncident myocardial infarction (95% confidence interval: 8%
o 44% greater; p  0.002). These associations were not
ppreciably altered by additional adjustment for calcium and
itamin D supplementation. Neither serum calcium nor
erum phosphorus concentrations were associated with any
f the cardiovascular outcomes in this study population.
To further address the possibility of confounding and to
xplore potential interactions, we estimated associations of
ower 25-OHD concentrations with mortality and myocar-
ial infarction across categories of physical activity level,
ody mass index, age, race, sex, and estimated kidney
unction (Fig. 2). Associations were generally similar, with
idely overlapping confidence intervals.
ssociations of PTH with study outcomes. After basic
djustment, serum PTH concentrations 65 pg/ml were
associated with cardiovascular death and incident heart
failure but not with all-cause mortality or myocardial in-
D  25
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with cardiovascular outcomes were confounded by kidney
function; adjustment for estimated GFR removed the sta-
tistical association with cardiovascular death and attenuated
the association with heart failure (Table 3, model 3). After
full adjustment, PTH concentrations 65 pg/ml remained
associated with an estimated 30% greater risk for heart
failure (95% confidence interval: 6% to 61% greater). This
association was not altered by excluding 21 subjects who
met the definition of primary hyperparathyroidism (adjusted
hazard ratio: 1.29; 95% confidence interval: 1.04 to 1.59) or
Baseline Characteristics by PTH and 25-OHD ConcentrationsTable 1 Baseline Characteristics by PTH and 25-OHD Concentr
Variable
25-O
>30
Number of participants 681 (29%) 1,
Demographic data
Age (yrs) 73 4
African Americans 30 (4%)
Men 287 (42%)
Season
Winter 112 (16%)
Spring 109 (16%)
Summer 286 (42%)
Autumn 174 (26%)
Site
Forsyth County, North Carolina 195 (29%)
Sacramento County, California 199 (29%)
Washington County, Maryland 152 (22%)
Pittsburgh, Pennsylvania 135 (20%)
Diabetes 55 (8%)
Medication use
Any antihypertensive agent 252 (37%)
Thiazide diuretic agent 56 (8%)
Loop diuretic agent 15 (2%)
Vitamin D supplement 10 (1.5%)
Calcium supplement 7 (1.0%)
Current smoking 54 (8%)
Education level
None through grade 9 73 (11%)
High school 256 (38%)
Professional/vocational 349 (51%)
Physical activity (kcal/week) 2,479 2,421 1,7
Physical examination data
Body mass index (kg/m2) 25.5 3.9 27
Systolic blood pressure (mm Hg) 134 20 1
Serum measurements
PTH (pg/ml) 49 27
25-OHD (ng/ml) 37 8
Calcium (mg/dl) 9.5 0.3 9
Phosphorus (mg/dl) 3.6 0.5 3
Estimated GFRcystatin C (ml/min/1.73 m
2) 75 18
CRP (mg/l) 4.3 8.5 4
Total cholesterol (mg/dl) 210 37 2
High-density lipoprotein (mg/dl) 57 16
Values are n (%) or mean  SD.
CRP  C-reactive protein; GFR  glomerular filtration rate; PTH  parathyroid hormone; 25-OHby additional adjustment for thiazide diuretic use (adjustedhazard ratio: 1.29; 95% confidence interval: 1.04 to 1.61).
When analyzed as a continuous variable, serum PTH was
not associated with any of the study outcomes.
Combined associations of 25-OHD and PTH with study
outcomes. The combination of vitamin D deficiency and
PTH excess tended to be associated with greater risks of
cardiovascular outcomes, but these differences were not
statistically significant (Table 4). We further looked for
evidence of additive interactions between serum 25-OHD
and PTH concentrations and cardiovascular events. The
relative excess risk of interaction was not statistically signif-
s
g/ml) PTH (pg/ml)
0 <15 <65 >65
4%) 384 (17%) 1,742 (75%) 570 (25%)
74 6 74 5 75 6
3%) 142 (37%) 226 (13%) 107 (19%)
7%) 79 (21%) 555 (32%) 146 (26%)
4%) 169 (44%) 413 (24%) 171 (30%)
4%) 118 (31%) 386 (22%) 143 (25%)
7%) 45 (12%) 538 (31%) 132 (23%)
4%) 52 (14%) 405 (23%) 124 (22%)
1%) 103 (27%) 513 (30%) 172 (30%)
1%) 94 (24%) 390 (22%) 167 (29%)
7%) 76 (20%) 449 (26%) 113 (20%)
1%) 111 (29%) 390 (22%) 118 (21%)
1%) 76 (20%) 196 (11%) 69 (12%)
9%) 187 (49%) 663 (38%) 262 (46%)
1%) 53 (14%) 183 (11%) 57 (10%)
%) 16 (4%) 39 (2%) 37 (7%)
%) 0 (0%) 8 (0.5%) 2 (0.4%)
.7%) 2 (0.5%) 16 (0.9%) 2 (0.4%)
0%) 58 (16%) 180 (10%) 48 (9%)
7%) 87 (23%) 262 (15%) 105 (18%)
8%) 145 (38%) 654 (38%) 216 (38%)
6%) 151 (39%) 823 (47%) 246 (43%)
,911 1,243 1,676 1,964 2,111 1,672 1,978
.8 27.9 5.5 26.4 4.5 27.8 5.4
1 140 21 135 20 142 23
6 71 39 44 12 94 37
11 3 27 10 21 9
.4 9.5 0.4 9.5 0.4 9.5 0.4
.5 3.6 0.5 3.6 0.5 3.5 0.5
8 76 19 77 17 72 20
.9 6.1 9.2 4.7 8.6 5.0 7.5
5 212 39 210 36 214 39
4 56 14 56 15 54 14
-hydroxyvitamin D.ation
HD (n
15–3
247 (5
74 5
160 (1
335 (2
303 (2
302 (2
339 (2
303 (2
387 (3
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334 (2
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131 (1
45 (4
0 (0
9 (0
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In this community-based cohort of ambulatory older adults
without clinical cardiovascular disease, lower serum 25-
OHD concentrations were associated with all-cause mor-
tality and incident myocardial infarction, whereas higher
serum PTH concentrations were associated with incident
heart failure. We did not detect an interaction of 25-OHD
and PTH on cardiovascular outcomes in this study popula-
tion. This study has several important strengths, which
include a generally healthy study population that was free of
clinical cardiovascular disease at baseline, more than twice
the length of follow-up compared with previous studies, a
large number of adjudicated cardiovascular events and car-
diovascular causes of death, and the use of standardized
methods to assess mineral metabolism markers, cardiovas-
cular risk factors, kidney function, and comorbid conditions.
In middle-aged populations, lower 25-OHD concentra-
tions are associated with incident myocardial infarction and
all-cause mortality (20,25,26). Associations of lower 25-
OHD concentrations with cardiovascular death, defined
using administrative codes, have recently been reported in
older populations from the U.S. and Europe (27,28).
owever, diagnosis codes and/or death certificate data are
nown to misclassify cardiovascular events and causes of
Associations of Serum 25-OHD Concentration With Study OutcomeTable 2 Associations of Serum 25-OHD Concentration With Stu
Variable Number Events
All-cause mortality 2,312 1,226
25-OHD 30 ng/ml 681 329
25-OHD 15–30 ng/ml 1,247 668
25-OHD 15 ng/ml 384 229
Continuous per 10 ng/ml lower 25-OHD
p value (continuous)
Cardiovascular mortality 2,312 389
25-OHD 30 ng/ml 681 107
25-OHD 15–30 ng/ml 1,247 207
25-OHD 15 ng/ml 384 75
Continuous per 10 ng/ml lower 25-OHD
p value (continuous)
Incident heart failure 2,312 504
25-OHD 30 ng/ml 681 107
25-OHD 15–30 ng/ml 1,247 207
25-OHD 15 ng/ml 384 75
Continuous per 10 ng/ml lower 25-OHD
p value (continuous)
Incident myocardial infarction 2,312 299
25-OHD 30 ng/ml 681 88
25-OHD 15–30 ng/ml 1,247 161
25-OHD 15 ng/ml 384 50
Continuous per 10 ng/ml lower 25-OHD
p value (continuous)
Values are n or adjusted hazard ratio (95% confidence interval). *Model 1 includes 25-OHD and p
2 adds diabetes, antihypertensive medications, smoking (never, current, former), education, kilo
high-density lipoprotein cholesterol, calcium, and phosphorus. ‡Model 3 adds estimated glomeru
25-OHD  25-hydroxyvitamin D.eath in older people (29,30).We found higher serum PTH levels to be associated with
an estimated 18% greater risk for cardiovascular death, but
this result was not statistically significant (95% confidence
interval: 0.92 to 1.50). In contrast, Hagström et al. (31)
reported a statistically significant association of higher PTH
concentrations with cardiovascular death among older
Swedish men. The relatively healthy makeup of our study
populations and more specific definition of cardiovascular
death in the CHS may have reduced study power to detect
associations with this outcome.
Lower serum 25-OHD concentrations represent decreased
vitamin D stores, whereas serum PTH excess reflects, in part,
inadequate biologic vitamin D activity (5,32,33). On the basis
of these relationships, we hypothesized that associations of
lower 25-OHD concentrations with cardiovascular outcomes
would be strongest in the presence of concomitant PTH
excess. However, our findings do not support such an interac-
tion. Moreover, 25-OHD and PTH concentrations tended to
be associated with different cardiovascular outcomes in this
study. These findings are more compatible with the hypothesis
that 25-OHD and PTH might influence cardiovascular risk
through divergent pathways.
The biologic actions of 25-OHD and PTH may explain
their associations with myocardial infarction and heart
failure. In previous studies, lower 25-OHD concentrations
utcomes
Model 1* Model 2† Model 3‡
1.00 1.00 1.00
1.14 (0.99–1.31) 1.10 (0.95–1.27) 1.15 (1.00–1.33)
1.36 (1.12–1.66) 1.21 (0.99–1.48) 1.29 (1.05–1.57)
1.10 (1.03–1.17) 1.05 (0.99–1.13) 1.09 (1.02–1.17)
0.005 0.122 0.012
1.00 1.00 1.00
1.00 (0.78–1.29) 0.95 (0.74–1.23) 1.01 (0.78–1.30)
1.24 (0.88–1.76) 1.08 (0.76–1.54) 1.17 (0.83–1.67)
1.07 (0.95–1.20) 1.02 (0.90–1.14) 1.06 (0.94–1.19)
0.247 0.795 0.356
1.00 1.00 1.00
1.00 (0.78–1.29) 0.95 (0.74–1.23) 1.01 (0.78–1.30)
1.24 (0.88–1.76) 1.08 (0.76–1.54) 1.17 (0.83–1.67)
0.99 (0.90–1.09) 0.92 (0.83–1.02) 0.95 (0.86–1.05)
0.861 0.100 0.303
1.00 1.00 1.00
1.17 (0.89–1.54) 1.17 (0.88–1.55) 1.20 (0.90–1.59)
1.41 (0.94–2.11) 1.37 (0.90–2.07) 1.40 (0.93–2.12)
1.25 (1.09–1.43) 1.23 (1.07–1.42) 1.25 (1.08–1.44)
0.001 0.004 0.002
oid hormone levels and is adjusted for age, race, sex, season of the year, and clinic site. †Model
of physical activity, body mass index, systolic blood pressure, levels of C-reactive protein, total,
tion ratecystatin C.sdy O
arathyr
calorieswere associated with metabolic risk factors for atheroscle-
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(34–36). Cell culture studies and in vivo animal models
have demonstrated immunomodulatory actions of vitamin
Figure 2 Association of 25-OHD Concentration With Mortality a
Continuous associations of 10 ng/ml lower 25-hydroxyvitamin D (25-OHD) concent
adjusted for the covariates in model 3. GFR  glomerular filtration rate.
Associations of Serum PTH Concentration WithTable 3 Associations of Serum PTH Concen
Variable Number Events
All-cause mortality
PTH 65 pg/ml 1,742 899
PTH 65 pg/ml 570 327
p value
Cardiovascular mortality
PTH 65 pg/ml 1,742 273
PTH 65 pg/ml 570 116
p value
Incident heart failure
PTH 65 pg/ml 1,742 351
PTH 65 pg/ml 570 153
p value
Incident myocardial infarction
PTH 65 pg/ml 1,742 223
PTH 65 pg/ml 570 76
p value
*Model 1 includes 25-hydroxyvitamin D and PTH levels and is adjusted
antihypertensivemedications, smoking (never, current, former), education
of C-reactive protein, total, high-density lipoprotein cholesterol, calcium, and pho
PTH  parathyroid hormone.D (8,37), and vitamin D increases insulin receptor expres-
sion and insulin responsiveness for glucose transport in
cultured human promonocytic cells (38). Hyperparathyroid-
yocardial Infarction by Subgroups
with all-cause mortality and incident myocardial infarction by subgroups,
y Outcomesn With Study Outcomes
Adjusted Hazard Ratio (95% Confidence Interval)
odel 1* Model 2† Model 3‡
1.00 1.00 1.00
(0.97–1.28) 1.14 (0.99–1.31) 1.07 (0.93–1.23)
0.125 0.035 0.341
1.00 1.00 1.00
(1.03–1.65) 1.30 (1.01–1.66) 1.16 (0.90–1.50)
0.030 0.040 0.213
1.00 1.00 1.00
(1.19–1.80) 1.40 (1.13–1.73) 1.30 (1.05–1.61)
0.001 0.003 0.018
1.00 1.00 1.00
(0.79–1.40) 1.01 (0.76–1.35) 0.98 (0.74–1.31)
0.719 0.994 0.793
, race, sex, season of the year, and clinic site. †Model 2 adds diabetes,
lories of physical activity, bodymass index, systolic blood pressure, levelsnd M
rationStudtratio
M
1.11
1.30
1.47
1.05
for age
, kilocasphorus. ‡Model 3 adds estimated glomerular filtration ratecystatin C.
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arterial stiffness and hypertension. The prevalence of hyper-
tension among patients with primary hyperparathyroidism
ranges from 30% to 70%, and blood pressure decreases after
surgical parathyroidectomy (39–41). PTH exerts a trophic
effect on cardiomyocytes, with an increase in total cellular
mass, and higher serum PTH concentrations are associated
with left ventricular hypertrophy in the general population
(11,42).
Study limitations. These observational data cannot prove
hat 25-OHD deficiency or PTH excess plays a causal role
n the development of cardiovascular disease. These sero-
ogic markers may be indicators of health status, in partic-
lar 25-OHD deficiency, which may reflect comorbidity,
ess time spent outdoors, and inadequate nutrient intake.
e attempted to address potential confounding in this
tudy by excluding individuals with pre-existing cardiovas-
ular diseases and by adjusting for lifestyle factors, comor-
idity, and cardiovascular risk factors that were measured
sing uniform methods. Adjusted models included some
actors that could reside on the hypothesized causal pathway
etween mineral metabolism disturbances and cardiovascu-
ar events, such as hypertension, diabetes, and inflammation.
djustment for estimated GFR using cystatin C levels was
articularly important for appreciating the confounding
nfluence of kidney function on the associations of PTH
ith cardiovascular mortality. A rise in serum PTH is 1 of
he first detectable mineral metabolism disturbances of
hronic kidney disease (43), which is highly prevalent in
lder adults and may be difficult to detect using traditional
Combined Associations of 25-OHD andPTH Concentrations With Study OutcomesTable 4 C mbined Associations of 25-OHD andPTH Concentrations With Study Outcomes
Variable
Adjusted Hazard Ratio
(95% Confidence Interval)
p Value for
InteractionPTH <65 pg/ml PTH >65 pg/ml
All-cause mortality
25-OHD 30 ng/ml 1.00 1.15 (0.82–1.60)
25-OHD 15–30 ng/ml 1.18 (1.01–1.37) 1.21 (0.98–1.49)
25-OHD 15 ng/ml 1.27 (1.00–1.61) 1.43 (1.11–1.85) 0.775
Cardiovascular mortality
25-OHD 30 ng/ml 1.00 0.97 (0.54–1.76)
25-OHD 15–30 ng/ml 0.96 (0.73–1.27) 1.20 (0.85–1.71)
25-OHD 15 ng/ml 1.15 (0.76–1.74) 1.32 (0.83–2.08) 0.745
Heart failure
25-OHD 30 ng/ml 1.00 1.35 (0.85–2.15)
25-OHD 15–30 ng/ml 1.03 (0.81–1.32) 1.39 (1.02–1.88)
25-OHD 15 ng/ml 0.85 (0.57–1.26) 0.95 (0.61–1.46) 0.774
Myocardial infarction
25-OHD 30 ng/ml 1.00 1.09 (0.58–2.02)
25-OHD 15–30 ng/ml 1.25 (0.92–1.70) 1.05 (0.68–1.62)
25-OHD 15 ng/ml 1.30 (0.79–2.13) 1.55 (0.91–2.62) 0.562
Hazard ratios adjusted for age, race, sex, season of the year, clinic site, diabetes, antihypertensive
medications, smoking (never, current, former), education, kilocalories of physical activity, body
mass index, systolic blood pressure, serum levels of C-reactive protein, total and high-density
lipoprotein cholesterol, calcium, phosphorus, and estimated glomerular filtration ratecystatin C.
PTH  parathyroid hormone; 25-OHD  25-hydroxyvitamin D.erologic markers.A second limitation of this study was the use of a single
measurement of 25-OHD and PTH later in life. Biologic
variation in these markers within an individual over time is
expected. The prospective design of this study favors non-
differential misclassification of 25-OHD and PTH concen-
trations, which would be expected to dilute the observed
associations. Future studies of mineral metabolism markers
and cardiovascular disease outcomes would benefit from
multiple measurements within a subject over time. The
CHS focused exclusively on older adults; associations of
mineral metabolism markers with cardiovascular events may
differ in younger and more ethnically diverse populations.
Conclusions
Consistent associations of 25-OHD concentrations with
cardiovascular outcomes across multiple cohort studies and
compelling biologic evidence for a beneficial effect of vita-
min D on cardiovascular health support clinical trials of
vitamin D therapy as the next step to test whether observed
associations are truly causal. Associations of PTH excess
with cardiovascular diseases are emerging and motivate
further epidemiological work in diverse populations to
better understand functional relationships and to determine
specific populations in which associations may be strongest.
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